Tvardi Therapeutics Inc. (TVRD) has an average rating of overweight and mean price target of $9.75, according to analysts polled by FactSet.
What else is happening in Research?
Research
Goldman Sachs Lifts Salik PT, Maintains Buy Rating
Goldman Sachs on Wednesday raised the price target for Dubai-based tollgate operator Salik (DFM:SALIK) to 7 Emirati dirhams from 6.80 dirhams, while maintaining its buy rating.
DFM:SALIK
Research
Citi Downgrades Lufthansa to Sell, Raises PT
Citi on Wednesday downgraded German airline company Deutsche Lufthansa (LHA.F) to sell from neutral and increased its price target to 8.70 euros from 8.20 euros.
$LHA.F
Research
Arqaam Capital Lowers Dubai Islamic Bank's PT, Keeps at Buy
Arqaam Capital on Tuesday reduced the price target for Emirati lender Dubai Islamic Bank (DFM:DIB) to 8.50 Emirati dirhams from 8.70 dirhams and affirmed its buy rating.
DFM:DIB